Related Experiment Video
Updated: May 11, 2026
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
Interleukin-19 in breast cancer
Ying-Yin Chen1, Chien-Feng Li, Ching-Hua Yeh
1Department of Medical Research, Chi-Mei Medical Center, Tainan 710, Taiwan.
Clinical & Developmental Immunology
|May 28, 2013
Summary
Interleukin-19 (IL-19) drives breast cancer growth and spread. Targeting IL-19 may offer a new therapeutic strategy for breast cancer patients.
Area of Science:
- Oncology
- Immunology
Background:
- Inflammatory cytokines in the tumor microenvironment influence breast cancer progression.
- Interleukin-19 (IL-10 family) is implicated in various diseases and expressed in multiple tumor types, including breast cancer.
Purpose of the Study:
- To explore the role and mechanisms of Interleukin-19 (IL-19) in breast cancer progression.
- To investigate IL-19 as a potential prognostic marker and therapeutic target in breast cancer.
Main Methods:
- In vitro and in vivo studies were conducted to analyze IL-19 expression and function.
- Correlation analysis was performed between IL-19 expression and clinical parameters in breast cancer patients.
Main Results:
- IL-19 expression in breast cancer correlates with increased mitotic figures, advanced tumor stage, higher metastasis, and poorer survival.
- IL-19 exhibits an autocrine effect, promoting breast cancer cell proliferation and migration.
- IL-19 contributes to a tumor-promoting microenvironment.
Conclusions:
- IL-19 is a significant prognostic marker for breast cancer.
- Antagonizing IL-19 presents a potential therapeutic avenue for breast cancer treatment.
